GLP-1 adoption in Vermont
Vermont has an estimated 25,304 GLP-1 users across 14 counties. Average estimated adoption is 1.8 percentage points below the national rate of 5.7%.
3.9%
Est. adoption rate
25,304
Est. users
28.9%
Avg adult obesity
643,816
Adult population
State facts for search and AI answers
What makes the Vermont GLP-1 page useful
This page ties the statewide answer to county-level demand, coverage context, and practical access checks. The goal is to help readers move from a broad state estimate to the local county or provider question that actually matters.
State signal
Vermont: 14 counties, 25,304 estimated GLP-1 users
State pages summarize the county-level demand model before readers drill into local pages.
Model inputs
Average adoption 3.9%; average adult obesity 28.9%
The model uses CDC PLACES obesity prevalence, Census population, and KFF national GLP-1 utilization.
Coverage context
Vermont Medicaid does not cover GLP-1s for obesity. Coverage for T2D, cardiovascular disease, and sleep apnea indications is still available. According to KFF (2026-01-16), federal Medicaid rules require GLP-1 coverage for type 2 diabetes, cardiovascular disease, and sleep apnea indications. Obesity coverage is optional and varies by state.
Coverage policy can make real access higher or lower than projected local demand.
How to use this page
Find counties with the strongest demand signal, then verify coverage, provider access, and pharmacy source before starting care.
This is a local planning page, not a prescription recommendation.
Counties ranked by estimated adoption
| Rank | County | Population | Obesity % | Est. adoption | Est. users |
|---|---|---|---|---|---|
| 1 | Franklin | 50,101 | 36.4% | 5.0% | 2,480 |
| 2 | Rutland | 60,585 | 35.5% | 4.8% | 2,926 |
| 3 | Essex | 5,976 | 34.1% | 4.6% | 277 |
| 4 | Orleans | 27,459 | 33.0% | 4.5% | 1,233 |
| 5 | Orange | 29,439 | 32.3% | 4.4% | 1,295 |
| 6 | Caledonia | 30,418 | 31.1% | 4.2% | 1,287 |
| 7 | Bennington | 37,326 | 30.8% | 4.2% | 1,564 |
| 8 | Grand Isle | 7,335 | 29.9% | 4.1% | 299 |
| 9 | Lamoille | 25,977 | 28.9% | 3.9% | 1,021 |
| 10 | Windsor | 57,832 | 28.7% | 3.9% | 2,261 |
| 11 | Addison | 37,434 | 28.1% | 3.8% | 1,430 |
| 12 | Washington | 59,768 | 27.1% | 3.7% | 2,205 |
| 13 | Windham | 45,857 | 26.0% | 3.5% | 1,623 |
| 14 | Chittenden | 168,309 | 23.6% | 3.2% | 5,403 |
How Vermont fits the national picture
The KFF 2024 poll pegged national adult GLP-1 use at 5.7%. Applied to Vermont's obesity profile, the model projects 3.9% of adults are on a GLP-1 medication. That matches the county-level obesity data from CDC PLACES (2023) more than any measured prescription count; the state's real share could be higher in urban areas with broad commercial coverage, or lower in rural regions where prescriber access is limited.
Compounded semaglutide and tirzepatide complicate the picture. After the FDA shortage resolution in late 2024 and early 2025, compounded supply dropped sharply. Brand-name utilization rose. The county numbers here don't separate brand vs. compounded, because no public dataset does yet.
Decision path
How should I use the Vermont GLP-1 map?
This state view is a demand and access signal, not a prescription recommendation. Use it to understand where GLP-1 need may be concentrated, then pressure-test provider availability, insurance rules, and pharmacy quality before starting care.
- State
- Vermont
- Counties
- 14
- Est. users
- 25,304
- Avg adoption
- 3.9%
Step 1
Find county context
County estimates help separate broad statewide demand from the local access picture a patient actually experiences.
Review countiesStep 2
Check coverage and price
Vermont access depends on payer policy, prior authorization, cash-pay pricing, and whether local clinicians can support follow-up.
Check coverage pathStep 3
Decide on care route
If local access is thin or pricing is unclear, a supervised telehealth assessment can clarify eligibility and next steps.
Compare provider optionsEvidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
CDC PLACES
DatasetUsed for county-level obesity inputs in local GLP-1 adoption estimates.
KFF GLP-1 utilization polling
DatasetUsed as the national anchor for estimated GLP-1 adoption.
STEP 1 semaglutide obesity trial
TrialPrimary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.
Frequently asked questions
How is GLP-1 adoption calculated for Vermont counties?
Why is Vermont's number 1.8 percentage points below the national average?
Do Medicaid enrollees in Vermont get GLP-1 coverage?
What studies back up GLP-1 weight loss expectations?
How often does the Vermont county data refresh?
Sources
- CDC BRFSS 2024 adult obesity prevalence, state-level
- CDC PLACES county-level obesity estimates, 2023 release
- KFF Health Tracking Poll 2024: one in eight US adults has taken a GLP-1
- US Census Bureau, American Community Survey 5-year estimates (2022).
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
Related reading
glp1
Compounded Semaglutide Guide
How compounded semaglutide access works, what to ask a pharmacy, and how to compare safety and pricing.
glp1
Semaglutide Cost Comparison
Compare semaglutide pricing across brand, insurance, cash-pay, and compounded access paths.
experience
Tirzepatide Side Effects Complete Guide
Common tirzepatide side effects, warning signs, and practical management steps to discuss with a clinician.
glp1
Semaglutide Injection Sites
How to rotate semaglutide injection sites and reduce irritation, bruising, and technique problems.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Looking for GLP-1 care in Vermont?
FormBlends ships compounded semaglutide and tirzepatide to Vermont with licensed telehealth consultations.
Start your assessmentEstimated adoption figures are modeled projections from public data, not measured prescription counts. This page is general information, not medical advice. Individual results vary. Talk to a licensed healthcare provider before starting any medication.